XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment Information
 12 Months Ended
Dec. 31, 2011
Segment Information

Note 11 — Segment Information

The Company operates in three reportable segments: (i) Cell Therapy — United States: (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. The Company’s operating businesses are organized based on the nature of markets and customers. The Company’s CEO, as chief operating decision maker, evaluates the results of operations along these reporting segments.

The Company’s financial information broken down by reportable segment was as follows (in thousands):

   
  Years Ended December 31,
     2011   2010
Revenues
                  
Pharmaceutical Manufacturing — China (products)   $ 63,393.6     $ 69,584.3  
Cell Therapy — United States (services)     10,050.1       181.1  
Regenerative Medicine — China (services)     274.3       55.9  
     $ 73,718.0     $ 69,821.3  
Loss from operations
                  
Pharmaceutical Manufacturing — China   $ (17,198.2 )    $ 8,475.9  
Cell Therapy — United States     (13,046.7 )      (9,690.4 ) 
Regenerative Medicine — China     (2,590.4 )      (1,427.1 ) 
Corporate office     (21,701.8 )      (16,236.7 ) 
     $ (54,537.1 )    $ (18,878.3 ) 

   
  December 31,
2011		   December 31,
2010
Total assets
                  
Pharmaceutical Manufacturing — China   $ 106,284.8     $ 125,133.7  
Cell Therapy — United States     40,653.1       1,241.2  
Regenerative Medicine — China     1,793.5       5,032.9  
Corporate office     6,596.4       11,616.9  
     $ 155,327.8     $ 143,024.7